Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

23andMe is a human genome research company enabling users to study their ancestry, genealogy, and inherited traits. A startup co-founded by Linda Avey and Anne Wojcicki, the wife of Google co-founder Sergey Brin, 23andMe has plans to make the human genome searchable. Brin, along with Google, gave 23andMe $3.9 million as part of a series A in May of 2007. The company was named after the number of chromosome pairs in humans. They aim to help people understand what their genes mean by indexing them and highlighting significant findings. 23andMe allows its clients/users to study their ancestry, genealogy, and inherited traits. The company also markets to researchers and scientists, for whom they provide neatly categorized and easily searchable data. One reason the Google investment in 23andMe made sense, was that this company could enable the search giant to index another facet of the world's information. With the Biotech and Health Care industries growing rapidly, 23andMe could help Google get and maintain a market hold in these already multi-billion dollar areas.

Part of Arches Holdings, Inc., Ancestry.com DNA LLC is a company headquartered in Provo, UT. The firm provides online network services for connecting families.

Illumina Cambridge Ltd. develops, manufactures and commercializes instruments, consumables and technologies for the analysis of DNA and genetic variation. The company was founded in 1998 and is headquartered in Saffron Walden, the United Kingdom.

Genomics plc aiming to lead the genomic transformation of healthcare, to develop and apply sophisticated analyses of massive integrated genomic and phenotypic datasets to learn about human biology and reveal the human wiring diagram They will lead the way through this challenge, using their expertise and experience to unleash the potential of genomics and set the standards by which organisations and patients can benefit from genomic data.

Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission-critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a company that places a high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, they strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic. David R. Walt, Satnam Alag, Larry Bock, and John Stuelpnagel co-founded Illumina in San Diego, California in 1998.

Part of Medtronic Plc, Covidien Pte Ltd. is a Singaporean company located in Singapore that manufactures and supplies medical equipment.

Celmatix is a next-generation women’s health company. They focus on reproductive health and fertility. Through their platform, they have amassed the largest structured dataset on ovarian health and outcomes in the world.

Ancestryhealth.com LLC, a subsidiary of Ancestry.com LLC, is an American company located in Provo, UT, that provides online network services for connecting families.

Expanding 4.5 million fixed lines to 20 million in just 12 years, kt introduced universal telephone service to every citizen of Korea, leading the development and advancement of communications services. More recently, kt established an advanced broadband network for the first time in Asia, and launched Korea's first communication satellite 'Mugunghwa (Sharon's Rose)', contributing to making Korea one of the most advanced countries in information and communications. Since becoming a government-funded corporation in 1997, kt changed its business portfolio to focus more on wireless and internet services instead of fixed lines. Taking over Hansol M.com and merging with its subsidiary KTF, kt expanded its business scope and included mobile communication as its main service. kt became a privately owned company in 2002 and began concentrating on building broadband network. As a result, the company set several new records including the increase of ADSL subscribers to 6 million in just 3 years and played a leading role in the age of digital networking.

Agric-Bioformatics is a data analytics company that provides user-interface and the intelligence to end-users to aggregate and visually analyze data. Our first product launch, AgBoost, is designed as a data driven tool specifically to aid livestock producers to optimally manage and selectively breed genetically superior animals. We aim to provide livestock producers an affordable, easy-to-use tool that allows for better access to , and understanding of , genomic information. Agric-Bioformatics overall goal is to help all livestock producers and Farmers to be more sustainable and improve productivity.

Signature Genomic Laboratories LLC was engaged in the provision of diagnostic cytogenetic services. It used microarray technology to diagnose chromosome abnormalities in children with developmental disabilities. The company was founded in 2003 and was headquartered in Spokane, WA.

Atlas Biomed Group Ltd. engages in operation of a personalized healthcare company. It applies genetic technologies to help you navigate towards potential. The company was founded by Sergey Musienko and is headquartered in London, the United Kingdom.

STALICLA is a clinical stage, precision molecular neuroscience biotech company with a mature pipeline for patients with Neurodevelopmental Disorders (NDDs) and Neuropsychiatric disorders. STALICLA’s unique approach addresses a principal weakness in the drug development process for NDD’s and neuropsychiatric disorders: behavior is a terrible biomarker. Clinical psychiatric and neurodevelopmental diagnoses encompass a broad diversity of underlying biology. This has contributed to drug development failure by diluting true responders in a population of patients with heterogeneous biology. STALICLA’s technology platform, DEPI, discovers biologically based endophenotypes within classical neuropsychiatric diagnostic groups. The AI/ML engine converges molecular data with human genetic information and non-behavioral clinical signs and symptoms, to define biologically related subgroups and create testable clinical hypotheses related to that biology. The DEPI platform has already completed several successful clinical validations, through the identification and biological validation of two distinct subgroups of patients with Autism Spectrum Disorder, ASD-Phenotype1 and ASD-Phenotype2, together with their predicted tailored treatment candidates (STP1 and STP2); as well as the blindly and retrospective calling “high” responder patients to previously failed drug candidates with high specificity, sensitivity, and positive predictive value. Further the completion of STP1 Phase 1b in 2022, STP1 will enter clinical Phase 2 in 2023; as well as STP2, a Phase 2 ready asset in licensed in Q4 ’22. Additionally, STALICLA will be advancing STP7, a recently in-licensed Phase 3 ready asset from Novartis, with strong potential for a neuropsychiatric indication, and whose clinical development will be fully financed by a non-dilutive funding to be announced in Feb. STALICLA is currently preparing its next stage of growth, to advance its pipelines and to scale its platform towards revenue generation.

Arc Bio is a bioscience company that provides microbial detection by developing novel metagenomic next-generation sequencing solutions. Their platform enables a sample-to-result integrated workflow that takes the user from a primary sample to quantitative results. Arc Bio revolutionizes microbial detection with turnkey metagenomic next-generation sequencing workflows and software solutions for fast, precise, and cost-effective analyses.

Sequencing is the world’s first and only open operating system for DNA sequencing, storage, analysis, personalization, and application development. We are ushering in a new era of personal genome innovation for consumers, bioinformatics developers/startups, pharmaceutical companies, and health and wellness providers. Sequencing has been used by partners throughout the world to develop and market more than 100 DNA analysis apps. These apps analyze data from our own or any third party genetic test (including 23andMe, Ancestry.com, Illumina, Invitae, and Color) and provide straightforward reports covering the full range of information that can be obtained from DNA including personalized medicine, preventive health, preconception screening, rare disease screening, wellness optimization, genealogy, and genetic data exploration. Our DNA-as-a-service enables healthcare providers and wellness organizations to effortlessly customize their own genetic testing, analysis, and storage pipelines for almost any purpose, including the assessment of risk for thousands of diseases, the likelihood of experiencing medication reactions, and the personalization of wellness products and services.

DnaNudge Ltd. provides genetic testing services. It offers DnaBand, DnaNudge, DnaNudge App and DnaNudgeBox brands. The company was founded by Maria Karvela and Christofer Toumazou on July 28, 2015 and is headquartered in London, the United Kingdom.

Bionomics Limited engages in the discovery and development of therapeutics for cancer and diseases of the central nervous system in Australia. It has small molecule product development programs in the areas of cancer, anxiety, epilepsy, and multiple sclerosis. The company develops its lead cancer compound, BNC 105, for the treatment of solid tumors, such as breast, lung, colon, and prostate cancers. BNC 105 is a member of the class of compounds, known as vascular disruption agents or VDAs, which shut down the blood supply within a tumor, starving the tumor and preventing its continued growth. The company has commercial partnerships with Genmab A/S; Athena Diagnostics; Laboratory Corporation of America; and Genetic Technologies, Ltd. Bionomics Limited was founded in 1999 and is based in Thebarton, Australia.

Part of Oracle Corp., Cerner Innovation, Inc. is a company headquartered in the United States specializing in information retrieval services.